Amyloidosis News and Research

RSS

Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.

Scientists discover novel compound to combat age-related blindness

Rensselaer Polytechnic Institute's Christopher Cioffi, Ph.D., Thomas and Constance D'Ambra Professor in Organic Chemistry, has been collaborating with Konstantin Petrukhin, Ph.D., Professor of Ophthalmic Science at Colombia University, to develop compounds to treat dry age-related macular degeneration (AMD) and Stargardt disease - both blindness-causing diseases.

28 Oct 2024

Boston University and GSK collaborate to tackle pulmonary fibrosis

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to advance innovative research focused on developing cutting-edge models to study and treat lung diseases like pulmonary fibrosis.

17 Oct 2024

NYU Langone researchers address the challenges of heart failure in cancer patients

A new scientific statement issued today by the Heart Failure Society of America highlights a critical connection between heart failure (HF) and cancer, with shared mechanisms contributing to the incidence and progression of both diseases.

16 Oct 2024

Plasma pTau181 predicts Alzheimer’s progression in real-world memory clinic patients

Researchers confirm plasma pTau181 is a strong predictor for Alzheimer's in patients with mild cognitive impairment, offering a less invasive diagnostic tool for early intervention.

20 Sep 2024

New biomarkers offer hope for early detection and prevention of Alzheimer's

The failure to diagnose Alzheimer's disease, the most common form of dementia in the elderly, at an early stage of molecular pathology is considered a major reason why treatments fail in clinical trials. Previous research to molecularly diagnose Alzheimer's disease yielded "A/T/N" central biomarkers based on the measurements of proteins, β-amyloid ("A") and tau ("T"), and "N" encompassing neurodegeneration. A/T/N can be measured in brain tissue, by in vivo brain imaging techniques, and by analysis of cerebrospinal fluid and plasma.

18 Sep 2024

New chemical modification reduces off-target effects in siRNA drugs

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases.

9 Sep 2024

Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Hereditary cardiac amyloidosis more common in the UK than previously thought

More people in the UK are at risk of a hereditary form of cardiac amyloidosis, a potentially fatal heart condition, than previously thought, according to a new study led by researchers at UCL (University College London) and Queen Mary University of London.

28 Aug 2024

Study uncovers roles of certain brain cells in Alzheimer's plaque formation

A study in Nature Neuroscience found that both neurons and oligodendrocytes contribute to amyloid-β plaque burden in Alzheimer's disease, highlighting new therapeutic targets.

7 Aug 2024

Transthyretin protein levels linked to heart failure and mortality

Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine have uncovered significant findings regarding the impact of transthyretin, or TTR, protein levels on heart disease risk.

29 Jul 2024

Associations between gut microbes and Alzheimer’s disease

Researchers reviewed existing data on the role of the gut microbiome in Alzheimer’s disease (AD) pathogenesis.

24 Jul 2024

Heart of the Matter: Early Diagnosis and Intervention in Heart Failure with Prof. Martin Cowie & Dr. Lisa Anderson

The future of heart failure treatment with AstraZeneca's Prof. Martin Cowie and Heart Failure Specialist and Consultant Cardiologist at St George’s Hospital Dr. Lisa Anderson.

17 Jul 2024

Enzymatic RNA synthesis paves the way for sustainable therapeutics

While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and amyloidosis.

12 Jul 2024

Antibody fragment discovery could lead to much-needed treatment for light chain amyloidosis

In people with a rare condition called light chain amyloidosis, light chain proteins - which are a component of antibodies - mutate and build up in different organs.

10 Jul 2024

60 years in the making: Nanoparticles revolutionize nucleotide delivery

Researchers trace the 60-year evolution of lipid nanoparticles (LNPs) for nucleic acid delivery, highlighting their potential to revolutionize gene therapy with safer and more effective treatments.

10 Jul 2024

Study uncovers role of Y chromosome loss in transthyretin cardiac amyloidosis

Researchers at Boston Medical Center (BMC) and Boston University (BU) Chobanian & Avedisian School of Medicine, in collaboration with an international team of scientists, shared findings from a new study published in the American Heart Association journal, Circulation: Heart Failure that explores a common cause of heart disease in older men called transthyretin cardiac amyloidosis (ATTR-CA).

27 Jun 2024